According to the SmPC, the following frequencies have been observed: Nausea (very common: may affect more than 1 in 10 people) Diarrhoea (very common: may affect more than 1 in 10 people) Vomiting (very common: may affect more than 1 in 10 people) Constipation (common: may affect up to 1 in 10 people) Abdominal pain and discomfort (common: may affect up to 1 in 10 people) Decreased appetite (very common: may affect more than 1 in 10 people) These effects typically diminish over time as the body adjusts to the medication, and gradual dose escalation helps minimise their severity
Early weight loss and improved control Steady progress often begins with noticeable changes on the scale for many patients
Circulation , 133 (4), e38e360
Recent studies have found that ACSL4 inhibits the increase of glioma cells by activating ferroptosis [72]
It is designed for regular use to prevent symptoms rather than to treat sudden attacks
Johnson & Johnson (US) Revenue 2025 (Pharmaceutical drug and vaccine sales): $60.40 billion 2024 (Pharmaceutical drug and vaccine sales): $57.80 billion 2023 (Pharmaceutical drug and vaccine sales): $54.80 billion Percent of revenue from pharmaceutical drug sales: 64.3% Estimated R&D spend: $14.60 billion Number of employees: 138,000 Revenue per employee: $680,000 Note: J&Js MedTech segment ($33.79B) is excluded from this ranking
